These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 4703880)

  • 21. Inhibition of 5-hydroxyindoleacetic acid transport from the spinal fluid by probenecid.
    Zivković B; Bulat M
    J Pharm Pharmacol; 1971 Jul; 23(7):539-40. PubMed ID: 4397456
    [No Abstract]   [Full Text] [Related]  

  • 22. On the elimination of 5-hydroxyindoleacetic acid and homovanillic acid from cerebrospinal fluid.
    Andersson H; von Essen C; Roos BE
    Acta Pharmacol Toxicol (Copenh); 1973; 32(1):129-38. PubMed ID: 4741033
    [No Abstract]   [Full Text] [Related]  

  • 23. 3-methoxy-4-hydroxyphenylglycol, 5-hydroxyindoleacetic acid, and homovanillic acid in human cerebrospinal fluid. Storage and measurement by reversed-phase high-performance liquid chromatography and coulometric detection using 3-methoxy-4-hydroxyphenyllactic acid as an internal standard.
    Javors MA; Bowden CL; Maas JW
    J Chromatogr; 1984 Dec; 336(2):259-69. PubMed ID: 6085084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transport mechanisms in the cerebrospinal fluid system for removal of acid metabolites from developing brain.
    Bass NH; Lundborg P
    Adv Exp Med Biol; 1976; 69():31-40. PubMed ID: 941740
    [No Abstract]   [Full Text] [Related]  

  • 25. Derivatization and gas chromatographic determination of some biologically important acids in cerebrospinal fluid.
    Watson E; Wilk S
    Anal Biochem; 1974 Jun; 59(2):441-51. PubMed ID: 4838778
    [No Abstract]   [Full Text] [Related]  

  • 26. Parkinsonism-dementia and amyotrophic lateral sclerosis of Guam. Effect of probenecid on monoamine catabolite levels in cerebrospinal fluid.
    Chase RN; Schnur JA; Brody JA; Gordon EK
    Arch Neurol; 1971 Jul; 25(1):9-13. PubMed ID: 5146413
    [No Abstract]   [Full Text] [Related]  

  • 27. Cerebrospinal fluid amine metabolites in affective illness: the probenecid technique.
    Goodwin FK; Post RM; Dunner DL; Gordon EK
    Am J Psychiatry; 1973 Jan; 130(1):73-9. PubMed ID: 4345466
    [No Abstract]   [Full Text] [Related]  

  • 28. Cerebrospinal fluid probenecid studies: a reinterpretation.
    Cowdry RW; Ebert MH; van Kammen DP; Post RM; Goodwin FK
    Biol Psychiatry; 1983 Nov; 18(11):1287-99. PubMed ID: 6197100
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid levels of 3-methoxy-4-hydroxyphenylethylene glycol in Parkinsonism before and after treatment with L-dopa.
    Wilk S; Mones R
    J Neurochem; 1971 Sep; 18(9):1771-3. PubMed ID: 5571114
    [No Abstract]   [Full Text] [Related]  

  • 30. Regional distribution and production rate of 3-methoxy-4-hydroxyphenylethyleneglycol sulphate (MHPG-SO4) in rat brain.
    Kohno Y; Tanaka M; Nakagawa R; Toshima N; Nagasaki N
    J Neurochem; 1981 Jan; 36(1):286-9. PubMed ID: 7463053
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychomotor activity and cerebrospinal fluid amine metabolites in affective illness.
    Post RM; Kotin J; Goodwin FK; Gordon EK
    Am J Psychiatry; 1973 Jan; 130(1):67-72. PubMed ID: 4682750
    [No Abstract]   [Full Text] [Related]  

  • 32. Monoamine metabolites in the CSF of epileptic patients.
    Laxer KD; Sourkes TL; Fang TY; Young SN; Gauthier SG; Missala K
    Neurology; 1979 Aug; 29(8):1157-61. PubMed ID: 37460
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Monoamine metabolites in human cerebrospinal fluid: indicators of neuronal activity?
    Scheinin M
    Med Biol; 1985; 63(1):1-17. PubMed ID: 2582215
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brain serotonin, affective illness, and antidepressant drugs: cerebrospinal fluid studies with probenecid.
    Goodwin FK; Post RM
    Adv Biochem Psychopharmacol; 1974; 11(0):341-55. PubMed ID: 4276863
    [No Abstract]   [Full Text] [Related]  

  • 35. Evidence for a probenecid-sensitive transport system of acid monoamine metabolites from the spinal subarachnoid space.
    Van der Poel FW; Van Praag HM; Korf J
    Psychopharmacology (Berl); 1977 Mar; 52(1):35-40. PubMed ID: 403555
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of probenecid on 5-hydroxyindoles in cerebrospinal fluid in Down's syndrome.
    Airaksinen EM; Kauko K
    Ann Clin Res; 1973 Dec; 5(6):392-4. PubMed ID: 4275983
    [No Abstract]   [Full Text] [Related]  

  • 37. Is cerebrospinal fluid the major avenue for the removal of 5-hydroxyindoleacetic acid from the brain?
    Meek JL; Neff NH
    Neuropharmacology; 1973 May; 12(5):497-9. PubMed ID: 4708479
    [No Abstract]   [Full Text] [Related]  

  • 38. Monoamine metabolite concentrations in the cerebrospinal fluid of normal and narcoleptic dogs.
    Faull KF; Barchas JD; Foutz AS; Dement WC; Holman RB
    Brain Res; 1982 Jun; 242(1):137-43. PubMed ID: 6179569
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Central administration of yohimbine increases free 3-methoxy-4-hydroxyphenylglycol in the cerebrospinal fluid of the rat.
    Mignot E; Laude D; Elghozi JL; Le Quan-Bui KH; Meyer P
    Eur J Pharmacol; 1982 Sep; 83(1-2):135-8. PubMed ID: 6182009
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Amine metabolism in the human brain: further evaluation of the probenecid test.
    Korf J; Van Praag HM
    Brain Res; 1971 Dec; 35(1):221-30. PubMed ID: 5134227
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.